I would like to publicly thank Joseph Moscato and his team, for the commitment and efforts made in trying to carry out the many initiatives of Generex.
I would also like to remind everyone of the difficulties that a small biopharma like Gnbt faces on its way: first of all, finding the necessary funds to advance with research.
I urge him to continue on this path, with the hope that, as he stated, "the pps will take care of itself" ...
Often the criticisms, including mine, are dictated by the exasperation of not seeing the work done by the Gnbt team materialized, in the price of the share.